Going beyond BCMA as a target in multiple myeloma

Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.

April 22, 2019
Aerial View Thames Estuary

Emerging Gamma Delta T Cell Cancer Immunotherapy Landscape

A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development

February 27, 2019

New developments in Multiple Myeloma

We take a look at several key developments in myeloma on the antibody and cell therapy front.

February 11, 2019

How do we improve on 1st Generation T cell bispecifics?

An upcoming small biotech focused on IO targets with their novel platform approach

January 28, 2019

The Yin and Yang of biomarkers in cancer research

Some examples of potentially useful biomarker inclusion in early oncology trials

January 22, 2019

A novel approach to cell therapy

Beyond T and NK cells, other immune cells can be used for cell therapies in solid tumours

January 4, 2019

Potential of CAR T cell therapy in CLL

How do we improve CAR-T cell therapy in CLL? A look at clinical data plus a new thought leader interview in the space.

December 10, 2018

ASH18 Highlights from Day 3

Review of a round dozen key abstracts at #ASH18, both scientific and clinical data is under the microscope!

December 3, 2018

ASH18 Highlights from Day 2

We offer 13 key highlights from day 2 of ASH18, including some surprises.

December 2, 2018

ASH18 Highlights from Day 1

Highlights from Day 1 of the 2018 ASH conference held in San Diego

December 1, 2018

ASH18 Preview 3 – BCMA

From one BCMA directed CAR in 2015, we now have a very competitive niche in multiple myeloma. What's in store?

November 26, 2018

ASH18 Preview 2 Late Breaking Abstracts

What to watch out for in the ASH18 LBA session

November 20, 2018

Creating order from the ASH18 data dump

A top-line review of the ASH18 abstract palooza

November 1, 2018